PHARMA-BIO SERV, INC.: capital expenditure payments
Capital expenditure payments for PHARMA-BIO SERV, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PHARMA-BIO SERV, INC. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-11-01 to 2025-10-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-11-01 | 2025-10-31 | 6,644 | USD | 2026-01-29 | 10-K · 0001654954-26-000710 |
| 2023-11-01 | 2024-10-31 | 159,743 | USD | 2026-01-29 | 10-K · 0001654954-26-000710 |
| 2022-11-01 | 2023-10-31 | 7,251 | USD | 2025-01-29 | 10-K · 0001654954-25-000915 |
| 2021-11-01 | 2022-10-31 | 19,269 | USD | 2024-01-29 | 10-K · 0001654954-24-000996 |
| 2020-11-01 | 2021-10-31 | 10,845 | USD | 2023-01-30 | 10-K · 0001654954-23-001018 |
| 2019-11-01 | 2020-10-31 | 55,657 | USD | 2022-02-11 | 10-K · 0001654954-22-001532 |
| 2018-11-01 | 2019-10-31 | 57,379 | USD | 2021-02-01 | 10-K · 0001654954-21-000973 |
| 2017-11-01 | 2018-10-31 | 122,009 | USD | 2020-01-29 | 10-K · 0001654954-20-000889 |
| 2016-11-01 | 2017-10-31 | 56,973 | USD | 2019-01-29 | 10-K · 0001654954-19-000854 |
| 2015-11-01 | 2016-10-31 | 1,808,632 | USD | 2018-01-29 | 10-K · 0001654954-18-000819 |
| 2014-11-01 | 2015-10-31 | 342,364 | USD | 2017-01-31 | 10-K · 0001654954-17-000601 |
| 2013-11-01 | 2014-10-31 | 207,507 | USD | 2016-01-29 | 10-K · 0001354488-16-006025 |
| 2012-11-01 | 2013-10-31 | 219,352 | USD | 2015-01-29 | 10-K · 0001354488-15-000359 |
| 2011-11-01 | 2012-10-31 | 187,362 | USD | 2014-01-29 | 10-K · 0001354488-14-000379 |
| 2010-11-01 | 2011-10-31 | 123,511 | USD | 2013-01-29 | 10-K · 0001354488-13-000352 |
| 2009-11-01 | 2010-10-31 | 45,429 | USD | 2012-01-31 | 10-K/A · 0001354488-12-000376 |
Related financial histories
- PHARMA-BIO SERV, INC.: total assets
- PHARMA-BIO SERV, INC.: total liabilities
- PHARMA-BIO SERV, INC.: stockholders equity
- PHARMA-BIO SERV, INC.: cash and cash equivalents
- PHARMA-BIO SERV, INC.: net income or loss
- PHARMA-BIO SERV, INC.: operating cash flow
- PHARMA-BIO SERV, INC.: revenue
- PHARMA-BIO SERV, INC.: financing cash flow
- PHARMA-BIO SERV, INC.: investing cash flow
- PHARMA-BIO SERV, INC.: retained earnings or deficit
- PHARMA-BIO SERV, INC.: basic weighted-average shares
- PHARMA-BIO SERV, INC.: diluted weighted-average shares
- PHARMA-BIO SERV, INC.: basic earnings per share
- PHARMA-BIO SERV, INC.: diluted earnings per share
- PHARMA-BIO SERV, INC.: income tax expense or benefit
- PHARMA-BIO SERV, INC.: net property, plant and equipment
- PHARMA-BIO SERV, INC.: share-based compensation expense
- PHARMA-BIO SERV, INC.: operating income or loss
- PHARMA-BIO SERV, INC.: current assets
- PHARMA-BIO SERV, INC.: interest expense
- PHARMA-BIO SERV, INC.: current liabilities
- PHARMA-BIO SERV, INC.: net current accounts receivable
- PHARMA-BIO SERV, INC.: common-stock repurchase payments
- PHARMA-BIO SERV, INC.: gross profit
- PHARMA-BIO SERV, INC.: cost of revenue
- PHARMA-BIO SERV, INC.: selling, general and administrative expense
Inspect the source
- Entity
- PHARMA-BIO SERV, INC. / CIK 0001304161
- Captured
- 2026-09-19T11:17:27.241Z
- SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))